Ipsen (Rights to Satoreotide) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Ipsen (Rights to Satoreotide) General Information

Description

Rights to an early clinical development proprietary peptide derivative that binds to somatostatin receptor 2 (SSTR2), which is overexpressed in neuroendocrine tumors and some aggressive cancers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Boulogne Billancourt
  • France
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Corporate Office
  • Boulogne Billancourt
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ipsen (Rights to Satoreotide) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ipsen (Rights to Satoreotide)‘s full profile, request access.

Request a free trial

Ipsen (Rights to Satoreotide) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ipsen (Rights to Satoreotide)‘s full profile, request access.

Request a free trial

Ipsen (Rights to Satoreotide) FAQs

  • Where is Ipsen (Rights to Satoreotide) headquartered?

    Ipsen (Rights to Satoreotide) is headquartered in Boulogne Billancourt, France.

  • What industry is Ipsen (Rights to Satoreotide) in?

    Ipsen (Rights to Satoreotide)’s primary industry is Buildings and Property.

  • Is Ipsen (Rights to Satoreotide) a private or public company?

    Ipsen (Rights to Satoreotide) is a Private company.

  • What is Ipsen (Rights to Satoreotide)’s current revenue?

    The current revenue for Ipsen (Rights to Satoreotide) is .

  • Who are Ipsen (Rights to Satoreotide)’s investors?

    Ipsen has invested in Ipsen (Rights to Satoreotide).

  • When was Ipsen (Rights to Satoreotide) acquired?

    Ipsen (Rights to Satoreotide) was acquired on 22-Oct-2021.

  • Who acquired Ipsen (Rights to Satoreotide)?

    Ipsen (Rights to Satoreotide) was acquired by Ariceum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process